HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 27.12
+0.59 (2.22%)
At close: Mar 6, 2026
HitGen Revenue
In the year 2025, HitGen had annual revenue of 525.57M CNY with 23.09% growth. HitGen had revenue of 155.78M in the quarter ending December 31, 2025, with 21.02% growth.
Revenue
525.57M
Revenue Growth
+23.09%
P/S Ratio
20.61
Revenue / Employee
1.09M
Employees
492
Market Cap
10.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 525.57M | 98.58M | 23.09% |
| Dec 31, 2024 | 426.99M | 55.66M | 14.99% |
| Dec 31, 2023 | 371.32M | 41.67M | 12.64% |
| Dec 31, 2022 | 329.65M | 18.59M | 5.98% |
| Dec 31, 2021 | 311.06M | 67.46M | 27.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 976.44M |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |